Apostolos Manolopoulos1, Panagiotis Andreadis1, Konstantinos Malandris1, Ioannis Avgerinos1, Thomas Karagiannis1, Dimitrios Kapogiannis2, Magda Tsolaki3, Apostolos Tsapas1,4, Eleni Bekiari1. 1. 1 Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece. 2. 2 Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, Bethesda, MD, USA. 3. 3 First Department of Neurology, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece. 4. 4 Harris Manchester College, University of Oxford, Oxford, United Kingdom.
Abstract
AIM: To assess the efficacy and safety of intravenous immunoglobulin (IVIg) for patients with Alzheimer's disease (AD). MATERIALS AND METHODS: We searched electronic databases and other sources for randomized controlled trials comparing IVIg with placebo or other treatment for adults with AD. Primary outcome was change from baseline in Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog). RESULTS: Five placebo-controlled trials were included in the meta-analysis. Compared to placebo, IVIg 0.2 and 0.4 g/kg once every two weeks did not change ADAS-Cog score (weighted mean difference: 0.37, 95% confidence interval: -1.46 to 2.20 and 0.77, -1.34 to 2.88, respectively). Furthermore, except for an increase in the incidence of rash, IVIg did not affect the incidence of other adverse events. CONCLUSION: IVIg, albeit safe, is inefficacious for treatment of patients with AD. Future trials targeting earlier stages of disease or applying different dosing regimens may be warranted to clarify its therapeutic potential.
AIM: To assess the efficacy and safety of intravenous immunoglobulin (IVIg) for patients with Alzheimer's disease (AD). MATERIALS AND METHODS: We searched electronic databases and other sources for randomized controlled trials comparing IVIg with placebo or other treatment for adults with AD. Primary outcome was change from baseline in Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog). RESULTS: Five placebo-controlled trials were included in the meta-analysis. Compared to placebo, IVIg 0.2 and 0.4 g/kg once every two weeks did not change ADAS-Cog score (weighted mean difference: 0.37, 95% confidence interval: -1.46 to 2.20 and 0.77, -1.34 to 2.88, respectively). Furthermore, except for an increase in the incidence of rash, IVIg did not affect the incidence of other adverse events. CONCLUSION: IVIg, albeit safe, is inefficacious for treatment of patients with AD. Future trials targeting earlier stages of disease or applying different dosing regimens may be warranted to clarify its therapeutic potential.
Authors: Richard Dodel; Axel Rominger; Peter Bartenstein; Frederik Barkhof; Kaj Blennow; Stefan Förster; Yaroslav Winter; Jan-Philipp Bach; Julius Popp; Judith Alferink; Jens Wiltfang; Katharina Buerger; Markus Otto; Piero Antuono; Michael Jacoby; Ralph Richter; James Stevens; Isaac Melamed; Jerome Goldstein; Stefan Haag; Stefan Wietek; Martin Farlow; Frank Jessen Journal: Lancet Neurol Date: 2013-01-31 Impact factor: 44.182
Authors: Susanne Ostrowitzki; Robert A Lasser; Ernest Dorflinger; Philip Scheltens; Frederik Barkhof; Tania Nikolcheva; Elizabeth Ashford; Sylvie Retout; Carsten Hofmann; Paul Delmar; Gregory Klein; Mirjana Andjelkovic; Bruno Dubois; Mercè Boada; Kaj Blennow; Luca Santarelli; Paulo Fontoura Journal: Alzheimers Res Ther Date: 2017-12-08 Impact factor: 6.982
Authors: Sonam Dubey; Stefan Heinen; Slavica Krantic; JoAnne McLaurin; Donald R Branch; Kullervo Hynynen; Isabelle Aubert Journal: Proc Natl Acad Sci U S A Date: 2020-12-07 Impact factor: 11.205
Authors: Samer R Khan; Amber Yaqub; M Kamran Ikram; P Martin van Hagen; Robin P Peeters; Virgil A S H Dalm; Layal Chaker; M Arfan Ikram Journal: J Neurol Date: 2022-09-19 Impact factor: 6.682